Pharmaceutical manufacturers of Ciprofloxacin

Aarti Drugs Ltd (ADL) is a part of the Aarti Group of Industries, which has a total worth of USD 500 million. It was established in 1984 and has since developed a strong presence in the fields of Anti-diarrhea and Anti-inflammatory therapeutic groups. The company's manufacturing facilities are located in Tarapur and Sarigam, where it produces a variety of medicines including Vitamins, Anti-arthritis, Anti-fungal, Antibiotics, ACE inhibitors, anti-diabetic, anti-cholinergic, sedatives, and anti-depressant drugs. Over the years, ADL has successfully carved a niche for itself and is now planning to increase its production capacity.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

HELM AG, a company based in Hamburg and owned by a family, has a 120-year history in 4 diverse sectors: Pharmaceuticals, Chemicals, Crop Protection, and Crop Nutrition. With a global presence through subsidiaries, sales offices, and partnerships, HELM is recognized as one of the world's leading independent marketing firms for chemicals. At HELM Pharma, our goal is to establish ourselves as the top B2B project and marketing platform, offering a distinctive partnership experience. In the marketing of our products, we deliver a comprehensive range of services for our business associates.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Bringing 86 years of expertise, UQUIFA'S operational approach is built on a fusion of a high-quality production platform and a proven history of service and dependability. UQUIFA specializes in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and RSM's for the pharmaceutical and animal health sectors on a global scale. The organization runs 2 production facilities (located in Spain and Mexico) with stringent compliance to all regulatory standards. These facilities operate under cGMP conditions and have undergone evaluation and endorsement from prominent global pharmaceutical companies.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

Dr. Reddy’s Laboratories Ltd. functions as an integrated pharmaceutical firm, dedicated to supplying cost-effective and innovative medications to promote healthier lifestyles. With a focus on Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, Dr. Reddy’s delivers a range of products and services such as APIs, customized pharmaceutical services, generics, biosimilars, and distinct formulations. The primary therapeutic areas of concentration encompass gastro-intestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s has a presence in various global markets, with significant engagements in the USA, Europe, India, Russia, and other CIS nations.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

Indoco Remedies Limited, based in India, is an emerging, fully integrated, research-oriented pharmaceutical firm with a global presence. We manufacture a diverse range of cost-effective, high-quality products in various therapeutic sectors that are widely embraced by healthcare professionals and clients across the globe. The company boasts a robust production infrastructure, a focus on Research & Development, and is uniquely positioned as a preferred collaborator providing comprehensive solutions to pharmaceutical companies marketing generics

DONGBANG FTL originated under the name Dongbang Synthetic Chemical with the aim of becoming the most well-known and reliable company in the active ingredients sector through honest competition

Smruthi Organics Ltd operates as an active pharmaceutical ingredient (API) manufacturing firm located in the country of India. With more than three decades of experience, we have been providing API to pharmaceutical firms worldwide. Our commitment to delivering top-notch API at competitive prices and within the set timelines has solidified our position as a key manufacturer of anti-diabetes, anti-hypertension, anti-platelet, and anti-infective API in India. Additionally, our API manufacturing facility holds GMP certification. Our proficient team of QA & Regulatory Affairs experts extends unparalleled technical and documentation support globally. Furthermore, we are publicly listed on the Bombay Stock Exchange (BSE).

Zhejiang Jingxin Pharmaceutical Co., Ltd. was established in 1990. It is a listed pharmaceutical company integrating R&D, production and sales. Following the business policy of "strengthening the main business of pharmaceuticals and developing medical devices", adhering to the core values ​​of "pragmatism, innovation, tolerance and win-win", and taking "carefully protecting health" as its mission, it is committed to becoming a leader in the fields of Chinese psychiatric, neurological, cardiovascular and cerebrovascular diseases...

Founded in October 2000, Zhejiang Guobang Pharmaceutical is a core enterprise of the Guobang Pharmaceutical Group. The company is located in the Hangzhou Bay Shangyu Economic and Technological Development Zone in Shangyu District, Shaoxing, Zhejiang Province, lying between the provincial capital of Hangzhou and the coastal city of Ningbo, in the hinterlands of the Yangtze River Delta economic region. It is well-connected to the transport network, with two sea bridges leading straight to Shanghai, as well as easy access to an airport, the high-speed rail, expressways, national highways, canals and ports. The company's core is in pharmaceutical manufacturing technology and it is engaged in the R&D, production, and operation for pharmaceutical and veterinary APIs and is a well-established manufacturer of synthetic APIs in China. The company's primary products are quinolones and macrolides and it is the world's leading producer of azithromycin, clarithromycin, roxithromycin, ciprofloxacin, enrofloxacin and marbofloxacin. Its production capacity and market share are above 35% in both the Chinese and international markets and its products are exported to 112 countries and regions, covering 6.5 billion people. Its sales network covers all regions of China and the US and European markets. The company is a national high-tech enterprise, with a national-level postdoctoral research station, a province-level pharmaceutical research institute, and a province-level enterprise technology center. It has received National Production Safety Standardization Certification, ISO 9001：2008 quality management certification and ISO 14001 environmental management system certification. All products have received national pharmaceutical and veterinary GMP certification, and all main products have received EUGMP, FDA, PMDA, ANVISA, MFDS and other certifications.

Ever since its establishment in 2000, Pharmacostech has played a prominent role in the fine chemical industry. The company has cultivated fundamental technologies, optimized manufacturing processes, and harnessed new discoveries from both internal and external laboratories. This includes the synthesis of novel chemicals and the development of environmentally-friendly processes, which have been successfully commercialized. In 2005, they commissioned a state-of-the-art GMP factory in Hwaseong, Gyeonggido, building upon their advanced technology. Today, Pharmacostech is embarking on its next challenge as a leading API producer.